Tempus AI's Q1 Earnings: Pharma Deals, Data Revenue Surge

Tempus AIs Q1 earnings call revealed a thriving data business, with CEO Eric Lefkofsky announcing massive deals like Merck and Gilead, pushing towards $410 million in data revenue next year. Theyve signed one hundred million dollar plus agreements with nearly half a dozen big pharmas, surpassing expectations. These wins mirror huge pacts with AstraZeneca, GSK, and BMS, but Gilead marks a significant step up. Despite delivering over eighty million dollars in revenue, total contract value grew in the quarter. Tempus five hundred petabyte oncology database dominates licensing, with new neurology plays like an Alzheimers model kicking off multimillion-dollar projects. Therapy selection volumes are up twenty percent, and MRD assays exploded five hundred percent, fueling twenty-five percent overall growth over three years toward adjusted EBITDA of sixty-five million dollars this year. With diversified engines from oncology to rare disease and data apps, Tempus sees billions ahead in the U.S. alone, building a comprehensive platform docs cant ignore. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6d09a7cbe339602c